Glyfloz-M 10/500 Tablet ER is a combination oral antidiabetic medication containing Dapagliflozin 10 mg and Metformin 500 mg extended-release. It is indicated for the management of type 2 diabetes mellitus in adults, particularly in patients inadequately controlled by diet and exercise alone. Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, reduces renal glucose reabsorption, promoting glycosuria and thereby lowering plasma glucose levels. Metformin, a biguanide, improves insulin sensitivity, decreases hepatic gluconeogenesis, and enhances peripheral glucose uptake, contributing to improved glycemic control. The extended-release formulation of Metformin ensures a gradual release, minimizing gastrointestinal side effects commonly associated with immediate-release forms. Glyfloz-M 10/500 Tablet ER is typically administered once daily with meals to optimize absorption and reduce gastrointestinal discomfort. This combination therapy offers complementary mechanisms of action, providing effective glycemic control while potentially aiding in weight reduction and cardiovascular risk mitigation. Patients should be monitored for signs of lactic acidosis, urinary tract infections, and volume depletion. Renal function assessment is recommended prior to initiation and periodically thereafter. Glyfloz-M 10/500 Tablet ER should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular monitoring of blood glucose levels.